close

Agreements

Date: 2016-12-19

Type of information: Development agreement

Compound: T-cell therapies

Company: Adaptimmune (UK) Bellicum Pharmaceuticals (USA - TX)

Therapeutic area: Cancer - Oncology

Type agreement: development, commercialisation

Action mechanism: cell therapy. Bellicum’s Chemical Induction of Dimerization (CID) technology platform was designed to address the challenges of current cellular immunotherapies by enabling control over cellular activities and functions, such as growth, activation, proliferation, persistence and survival. This platform consists of molecular switches—modified forms of signaling proteins—which are triggered inside the patient by infusion of small molecule rimiducid, instead of by natural upstream signals. Adaptimmune’s proprietary Spear® (Specific Peptide Enhanced Affinity Receptor) T-cell receptor (TCR) technology enables the company to genetically optimize TCRs in an effort to equip them to recognize and bind cancer antigens that are presented in small quantities on the surface of a cancer cell, whether of intracellular or extracellular origin, thus initiating cell death.

Disease:

Details: * On December 19, 2016, Adaptimmune Therapeutics and Bellicum Pharmaceuticals announced that they have entered into a staged collaboration to evaluate, develop, and commercialize next-generation T-cell therapies. Under the agreement, the companies will evaluate Bellicum’s GoTCR technology (inducible MyD88/CD40 co-stimulation) with Adaptimmune’s affinity-optimized Spear® T-cells for the potential to create enhanced TCR product candidates. Depending on results from the preclinical proof-of-concept phase, the companies expect to progress to a two-target co-development and co-commercialization phase.  

Financial terms:

Latest news:

Is general: Yes